Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma

认证基因工程临床相关的多发性骨髓瘤小鼠模型

基本信息

批准号：
10053331
负责人：
Marta Chesi
金额：
$ 37.97万
依托单位：
MAYO CLINIC ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-12-07 至 2023-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10053331
关键词：
Address Amino Acid Sequence Anemia B-Lymphocytes Bacterial Artificial Chromosomes Binding Biological Biological Models Biology Bone Diseases Bone Marrow Cell Line Cell Survival Cell Transplantation Cells Clinical Combination Drug Therapy Combined Modality Therapy Complex Credentialing Dependence Drug Receptors Drug resistance Drug usage Engineering Generations Genes Genetic Genetic Engineering Genomic approach Glucocorticoids Goals Hematologic Neoplasms Home Human Human Characteristics Immune system Immunocompetent Immunoglobulin Class Switching Immunoglobulin Somatic Hypermutation Immunoglobulins Immunomodulators Immunotherapy Impairment Indolent Interferon Type II Kidney Mediating Modeling Monoclonal gammopathy of uncertain significance Multiple Myeloma Mus Mutation Newly Diagnosed Patients Pharmaceutical Preparations Population Pre-Clinical Model Precancerous Conditions Predictive Value Proteasome Inhibitor Publishing Refractory Regulatory Element Relapse Research Personnel Resistance Role Splenocyte Structure of germinal center of lymph node T-Cell Proliferation Thalidomide Transcription Factor 3 Transgenic Mice Transplantation Ubiquitin Validation Variant Vertebral column Work clinical practice clinical predictors clinically relevant drug-sensitive experimental study gene product genetic manipulation human disease in vivo in vivo Model lenalidomide mouse model neoplasm immunotherapy neoplastic cell novel plasma cell differentiation pleiotropism pomalidomide post-transplant receptor recruit relapse patients response tumor tumor immunology tumor progression

项目摘要

Project Summary/Abstract Thalidomide (Thal) and its derivatives, Lenalidomide (Len) and Pomalidomide (POM), are immune modulatory drugs (IMiDs) used in the treatment of multiple myeloma (MM) and few other hematological malignancies. Although they represent the backbone treatment for both newly diagnosed and relapse/refractory MM patients, their clinical use remains mostly empirical because of lack of suitable in vivo model systems to study their complex mechanisms of action. Murine cells are intrinsically resistant to IMiDs because of different amino acid sequence in the IMiD binding domain of cereblon (CRBN). By building upon our extensively validated Vk*MYC transgenic mouse model of MM, we have generated a novel transgenic mouse, Vk*MYChCRBN, expressing the full human CRBN (hCRBN) gene under the control of its endogenous regulatory elements, rendering it IMiD sensitive. As previously done for the Vk*MYC model, we will extensively characterize the new Vk*MYChCRBN model and will use it to understand the IMiD effects on the tumor and the immune system with the ultimate goal to inform clinical practice.

项目概要/摘要沙利度胺 (Thal) 及其衍生物来那度胺 (Len) 和泊马度胺 (POM) 具有免疫能力用于治疗多发性骨髓瘤 (MM) 和少数其他疾病的调节药物 (IMiD) 血液系统恶性肿瘤。尽管它们代表了新疗法的骨干治疗对于已诊断的和复发/难治性 MM 患者，其临床应用仍然主要是经验性的，因为缺乏合适的体内模型系统来研究其复杂的作用机制。小鼠细胞是由于 IMiD 结合域中的氨基酸序列不同，因此对 IMiD 具有内在抗性大脑（CRBN）。通过建立我们广泛验证的 Vk*MYC 转基因小鼠模型 MM，我们已经培育出一种新型转基因小鼠，Vk*MYChCRBN，表达完整的人类 CRBN (hCRBN) 基因受其内源性调控元件控制，使其对 IMiD 敏感。正如之前对 Vk*MYC 模型所做的那样，我们将广泛描述新的 Vk*MYChCRBN 模型，并将用它来了解 IMiD 对肿瘤和免疫系统的影响最终目标是为临床实践提供信息。